YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
In today's Just The Facts.. archTIS has deployed its NC Protect software into the U.S. Department of Defense’s Microsoft DoD365 production environment. The company has also renewed 1,000 licences and says discussions toward a large-scale e…
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dose…
As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or newer companies, continue to attract a…
Australian shares are showing signs of consolidation after a recent bullish surge, with the ASX 200 futures indicating a slight decline. Amid such market dynamics, investors often seek opportunities in lesser-known areas like penny stocks,…
Australian shares are showing resilience as they head into Week 31 with a slight uptick, buoyed by a significant trade deal between the U.S. and European Union that promises to bring stability to global markets. In such an environment, inv…
Amicus Therapeutics, Inc.; Dimerix Limited Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidne…